Future research should investigate the interplay between UBAP2L-dependent SG functions and broader metabolic or immune pathways in ccRCC, as well as validate OGT inhibition in preclinical and clinical settings. The gene discussed is OGT; the disease is nonpapillary renal cell carcinoma.